Publication date: Feb 01, 2025
Subgenomic RNAs (sgRNAs) are potential markers of active SARS-CoV-2 replication, serving as templates for the synthesis of structural and accessory proteins in infectious viral particles. This study aimed to use RT-qPCR to quantify sgRNA and negative RNA intermediates, assessing viral replication in virus samples inactivated by β-propiolactone (βPL). Inactivated viruses subjected to five blind serial passages (BSs) were amplified by RT-qPCR using primers to target the envelope (ENV) and nucleoproteins (N1 and N2) of genomic genes, subgenomic envelope RNA (sgENV), and intermediate envelope RNA (ENV-). All positive controls showed consistent viral titers across passages (10 log10 copies/mL in N1/N2 and 11 log10 copies/mL in ENV) during BSs. Inactivated viral samples for ENV and ENV- targets ranged from 11. 34 log10 copies/mL in BS1 to 11. 20 log10 copies/mL in BS5. The sgENV was no longer detected in the inactivated SARS-CoV-2 samples after the second passage, suggesting successful inactivation. Replication kinetics showed consistent profiles for N1/N2, ENV, and ENV- targets in the first three post-infection hours (pih) and maintained approximately 5 log10 copies/mL at 1 pih, 2 pih, and 3 pih. A sharp exponential increase in the viral titer was observed from 24 pih onwards, peaking at 11. 64 log10 copies/mL at 48 pih. Transmission electron microscopy confirmed viral particles only in cells infected with active SARS-CoV-2. These results support the use of sgRNA as a reliable marker for SARS-CoV-2 replication, especially in distinguishing between active replication and non-viable particles and in the development of diagnostic and therapeutic strategies.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | IDO | replication |
pathway | KEGG | Viral replication |
drug | DRUGBANK | Propiolactone |
disease | MESH | infection |
drug | DRUGBANK | Ribostamycin |
drug | DRUGBANK | Coenzyme M |
disease | MESH | viral load |
disease | IDO | production |
drug | DRUGBANK | Tretamine |
disease | IDO | infectivity |
disease | IDO | assay |
disease | IDO | cell |
disease | MESH | SARS CoV 2 infection |
drug | DRUGBANK | Gold |
disease | IDO | nucleic acid |
drug | DRUGBANK | Trestolone |
disease | IDO | facility |
disease | MESH | viral infection |
drug | DRUGBANK | Sorbitol |
drug | DRUGBANK | Trypsin |
drug | DRUGBANK | Sucrose |
drug | DRUGBANK | Copper |
drug | DRUGBANK | Silicon dioxide |
drug | DRUGBANK | Water |
drug | DRUGBANK | Spinosad |
disease | MESH | Influenza |
drug | DRUGBANK | Guanosine |
drug | DRUGBANK | (S)-Des-Me-Ampa |
drug | DRUGBANK | Methylergometrine |